What You Ought to Know:
– Guardant Health, a supplier in precision oncology, and ConcertAI, a real-world proof (RWE) and AI expertise firm in oncology, introduced a strategic collaboration that can present biopharmaceutical corporations with entry to a first-of-its-kind multi-modal real-world knowledge (RWD) resolution.
– The partnership integrates complete affected person electronic medical record (EMR) knowledge with genomic and epigenomic tumor profiling info, providing a deeper understanding of most cancers biology and remedy response.
Enhanced Most cancers Analysis and Growth
Most cancers is a posh illness, and a affected person’s response to remedy might be influenced by numerous components, together with particular genetic mutations, prior therapies, and the event of drug resistance. This new joint RWD resolution gives vital scientific context to an intensive database of strong tumor most cancers sufferers with a number of liquid biopsies. This enables biopharma researchers to:
- Higher interpret illness biology: Achieve a extra complete understanding of the underlying mechanisms driving most cancers development.
- Determine drivers of tumor evolution: Pinpoint the precise genetic and epigenetic modifications that contribute to tumor development and unfold.
- Perceive resistance mechanisms: Uncover how tumors develop resistance to therapies, each intrinsically and over time.
By leveraging this complete dataset, mixed with the analytics capabilities and AI SaaS options of each ConcertAI and Guardant Well being, biopharmaceutical corporations can acquire a deeper understanding of most cancers and develop simpler remedies.
“Realizing the potential of precision medication requires a complete, multi-dimensional understanding of the tumor, the scientific atmosphere and the affected person’s response to remedy,” mentioned Helmy Eltoukhy, Guardant Well being co-CEO. “This partnership between Guardant and ConcertAI offers proof and outcomes researchers entry to intensive, strong knowledge and AI-based modeling that may present unprecedented perception right into a affected person’s most cancers journey, together with a tumor’s advanced systemic interactions, to assist them speed up the event of much-needed most cancers therapies. It represents one other milestone in Guardant’s mission to beat most cancers with knowledge.”
